Acumen Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Oct 26, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Changes in Stockholders’ Equity
(in thousands, except share data)
For the Three Months Ended September 30, 2026
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveLoss · TotalStockholders’Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance as of June 30, 2026 | 72,314,714 | $7 | $557,186 | $(499,917) | $(13) | $57,263 | |||||
| Stock options exercised for cash | 12,606 | — | 22 | — | — | 22 | |||||
| Unrealized loss on marketable securities | — | — | — | — | (12) | (12) | |||||
| Stock-based compensation | — | — | 2,706 | — | — | 2,706 | |||||
| Net loss | — | — | — | (25,369) | — | (25,369) | |||||
| Balance as of September 30, 2026 | 72,327,320 | $7 | $559,914 | $(525,286) | $(25) | $34,610 | |||||
For the Three Months Ended September 30, 2025
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome · TotalStockholders’Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance as of June 30, 2025 | 60,573,425 | $6 | $511,921 | $(394,873) | $23 | $117,077 | |||||
| Unrealized gain on marketable securities | — | — | — | — | 86 | 86 | |||||
| Stock-based compensation | — | — | 2,461 | — | — | 2,461 | |||||
| Net loss | — | — | — | (26,451) | — | (26,451) | |||||
| Balance as of September 30, 2025 | 60,573,425 | $6 | $514,382 | $(421,324) | $109 | $93,173 | |||||
Condensed Statements of Changes in Stockholders’ Equity
(in thousands, except share data)
For the Nine Months Ended September 30, 2026
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensive Income (Loss) · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2025 | 60,575,369 | $6 | $516,803 | $(446,462) | $83 | $70,430 |
| Issuance of common stock in connection with the private placement, net of offering costs of $309 | 10,833,331 | 1 | 35,440 | — | — | 35,441 |
| Issuance of common stock for restricted stock units, net of shares withheld for taxes | 791,052 | — | (149) | — | — | (149) |
| Stock options exercised for cash | 127,568 | — | 194 | — | — | 194 |
| Unrealized loss on marketable securities | — | — | — | — | (108) | (108) |
| Stock-based compensation | — | — | 7,626 | — | — | 7,626 |
| Net loss | — | — | — | (78,824) | — | (78,824) |
| Balance as of September 30, 2026 | 72,327,320 | $7 | $559,914 | $(525,286) | $(25) | $34,610 |
For the Nine Months Ended September 30, 2025
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2024 | 60,094,083 | $6 | $506,985 | $(325,127) | $(48) | $181,816 |
| Issuance of common stock for restricted stock units, net of shares withheld for taxes | 446,756 | — | (73) | — | — | (73) |
| Stock options exercised for cash | 32,586 | — | 37 | — | — | 37 |
| Unrealized gain on marketable securities | — | — | — | — | 157 | 157 |
| Stock-based compensation | — | — | 7,433 | — | — | 7,433 |
| Net loss | — | — | — | (96,197) | — | (96,197) |
| Balance as of September 30, 2025 | 60,573,425 | $6 | $514,382 | $(421,324) | $109 | $93,173 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.